Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQH 2722

Next Previous
Drug Profile

TQH 2722

Alternative Names: TQH-2722

Latest Information Update: 15 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Developer Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical
  • Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 4 receptor type I antagonists; Interleukin-4 receptor type II antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Seasonal allergic rhinitis; Sinusitis

Most Recent Events

  • 01 Jul 2025 Chia Tai Tianqing Pharmaceutical Group completes a phase II trial in Seasonal allergic rhinitis (Treatment-experienced) in China (Injection) (NCT06760182)
  • 30 Apr 2025 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical completes the Phase-II clinical trials in Sinusitis in China (Injection) (NCT06089278)
  • 10 Mar 2025 Phase-II clinical trials in Seasonal allergic rhinitis (Treatment-experienced) in China (Injection) (NCT06760182)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top